Allergic Conjunctivitis (AC) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Summary
This reports provides a data-driven overview of the current and future competitive landscape in AC therapeutics.
There will be more than 1 billion prevalent cases of AC in 2023 in the 16 countries covered in GlobalData’s epidemiology forecast for AC.
The innovator marketed drugs space for AC mainly consists of dual-acting antihistamines and mast cell inhibitors.
R&D activity in AC is promising with four drugs in Phase III and 10 drugs in Phase II of development.
Clinical trial space in AC mainly includes commercial sponsors, with the US emerging as the key country for conducting Phase III trials.
Two strategic alliances and one merger & acquisition involving companies developing AC assets were successfully completed in the past two years.
Scope
GlobalData’s Allergic Conjunctivitis (AC) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include-
Disease Landscape
Disease Overview
Epidemiology Overview
Treatment Overview
Marketed Products Assessment
Breakdown by Mechanism of Action, Molecule Type, Route of Administration
Product Profiles with Sales Forecast
Pricing and Reimbursement Assessment
Annual Therapy Cost
Time to Pricing and Time to Reimbursement
Pipeline Assessment
Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
Product Profiles with Sales Forecast
Late-to-mid-stage Pipeline Drugs
Phase Transition Success Rate and Likelihood of Approval
Clinical Trials Assessment
Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
Enrolment Analytics, Site Analytics, Feasibility Analysis
Deals Landscape
Mergers, Acquisitions, and Strategic Alliances by Region
Overview of Recent Deals
Commercial Assessment
Key Market Players
Future Market Catalysts
Reasons to Buy
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the AC market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global AC market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Key Findings
Disease Overview
Epidemiology Overview
Epidemiology Overview: Total Prevalent Cases of AC in 2023 and 2028
Treatment Overview
Treatment Guidelines
Treatment Algorithm
Marketed Drugs Assessment
Marketed Drugs - Leading Marketed Drugs in AC
Marketed Drugs - Overview by Mechanism of Action
Marketed Drugs - Overview by Molecule Type
Marketed Drugs - Overview by Route of Administration
Marketed Drug Profile: Aytu BioPharma/Tris Pharma’s Karbinal ER
Marketed Drug Profile: Eyevance Pharmaceuticals’s Zerviate
Marketed Drug Profile: Ocular Therapeutix’s Dextenza
Marketed Drug Profile: Johnson & Johnson’s Ketotifen Fumarate
Marketed Drug Profile: Novartis’s Pazeo
Marketed Drug Profile: Boehringer Ingelheim’s Alesion/Alesion LX/Elestat/ Purivist/Relestat
Marketed Drug Profile: Stallergenes Greer’s Alustal 5 Grasses and Rye/Alustal Beifuss/Oralair/Oraleyr/Phostal 5 Grasses and Rye/Phostal Beifuss
Pricing and Reimbursement Assessment
Marketed Drugs - Annual Therapy Cost
Pipeline Drugs Assessment
Pipeline Drugs Overview - Late-to-mid-Stage Pipeline Drugs in AC
Pipeline Drugs - Overview by Development Stage
Pipeline Drugs - Overview by Mechanism of Action
Pipeline Drugs - Overview by Molecule Type
Pipeline Drugs - Overview by Route of Administration
Pipeline Drugs - Drug-Specific Phase Transition Success Rate and Likelihood of Approval in AC
Pipeline Drugs - Phase Transition Success Rates and Likelihood of Approval in Ophthalmology and in AC
Clinical Trials Assessment
Clinical Trials in AC - Historical Overview
Clinical Trials in AC - Overview by Phase
Clinical Trials in AC - Overview by Status
Clinical Trials in AC - Overview by Phase for Ongoing and Planned Trials
Clinical Trials in AC - Trials with a Virtual Component
Clinical Trials in AC - Number of Trials by Geography
Clinical Trials in AC - Single-Country and Multinational Trials by Region
Clinical Trials in AC - Top 20 Sponsors with Breakdown by Phase
Clinical Trials in AC - Top 20 Sponsors with Breakdown by Status
Clinical Trials in AC - Overview by Endpoint Status
Clinical Trials in AC - Overview by Race and Ethnicity
Clinical Trials in AC - Enrollment Data
Clinical Trials in AC - Overview of Sites by Geography
Clinical Trials in AC - Top 20 Countries for Trial Sites